
- /
- Supported exchanges
- / US
- / INKT.NASDAQ
Mink Therapeutics Inc (INKT NASDAQ) stock market data APIs
Mink Therapeutics Inc Financial Data Overview
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; and ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Mink Therapeutics Inc data using free add-ons & libraries
Get Mink Therapeutics Inc Fundamental Data
Mink Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -9 778 765
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-12
- EPS/Forecast: -0.15
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mink Therapeutics Inc News

Tuesday Sector Laggards: General Contractors & Builders, Biotechnology Stocks
In trading on Tuesday, general contractors & builders shares were relative laggards, down on the day by about 2.9%. Helping drag down the group were shares of Hovnanian Enterprises off about 4.4% and...


MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy
NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies,...

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.20%
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Financials, Consumer Services and Industrials sectors led shares higher. At the close in NYSE, the Dow Jones Indus...

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.63%
Investing.com – U.S. stocks were lower after the close on Friday, as losses in the Telecoms, Healthcare and Financials sectors led shares lower. At the close in NYSE, the Dow Jones Industrial Avera...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.